Receptor News and Research

RSS

Breakthrough discovery could pave the way for new non-opioid painkillers to treat neuropathic pain

Monash University researchers have made a breakthrough discovery that could pave the way for the development of novel non-opioid painkillers to safely and effectively treat neuropathic pain.

8 Sep 2021

The role of nanobodies in capturing and containing SARS-CoV-2

Scientists have repurposed the Nb Ty1 for the detection and neutralization of SARS-CoV-2.

8 Sep 2021

$New tool can rapidly quantify T cell fraction and predict immunotherapy response$

New tool can rapidly quantify T cell fraction and predict immunotherapy response

Scientists at UCL and the Francis Crick Institute, London, have developed a new tool, which can rapidly estimate the number of T cells (immune cells) in a cancerous tumor; with T cell abundance helping predict a patient's response to immunotherapy, researchers are hopeful this could enable more targeted and effective cancer therapies.

8 Sep 2021

Potential pancoronavirus fusion inhibitors that are effective against SARS-CoV-2 variants

A new study successfully identifies a series of inhibitors that possesses pancoronavirus activity against SARS-CoV, SARS-CoV-2, and MERS-CoV.

7 Sep 2021

Activated mast cell disorders potentially linked to SARS-CoV-2 immunity

An intriguing new study reports a year-long study in patients with cMCADs from all over France.

7 Sep 2021

Multiplexed electrochemical sensor platform enables simultaneous detection of SARS-CoV-2 RNA and host antibodies

Scientists from the UK and USA have developed an antifouling nanocomposite-coated multiplexed electrochemical sensor platform that can simultaneously detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA and virus-specific antibodies. The platform has shown 100% accuracy in detecting viral RNA and IgG-specific anti-SARS-CoV-2 antibodies. The study is currently available on the medRxiv* preprint server.

6 Sep 2021

Implications of persistent SARS-CoV-2 infection in patients with lymphoid malignancies

In a recent study, scientists attempt to understand persistent COVID-19 and its implications in patients with hematologic malignancies.

6 Sep 2021

Maternal SARS-CoV-2 vaccination in early-third trimester may optimize neonatal seroprotection

Researchers in Israel have conducted a study showing that vaccinating pregnant women against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) early on in the third trimester may maximize transplacental antibody transfer, potentially helping to prevent severe coronavirus disease 2019 (COVID-19) during infancy.

6 Sep 2021

Study sheds light on neurologic symptoms caused by SARS-CoV-2 infection

Researchers in Australia and Finland have provided important insights into how infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – might affect nervous system circuitries and cause neurologic symptoms.

6 Sep 2021

Increased infectivity and immune evasion drive the spread of Delta SARS-CoV-2 variant

Findings suggest infection control measures against variants will need to continue in the post-vaccination era.

6 Sep 2021

New insights could help unlock the mystery of how lung cancer arises in never smokers

A genomic analysis of lung cancer in people with no history of smoking has found that a majority of these tumors arise from the accumulation of mutations caused by natural processes in the body.

6 Sep 2021

Decreased COVID-19 vaccine efficacy amongst IBS patients receiving anti-TNFα drugs

In a paper recently uploaded to the preprint server medRxiv* by Edelman-Klapper et al., the efficacy of the mRNA vaccine is examined amongst IBD patients and compared with healthy volunteers, finding reduced efficacy amongst those receiving anti-TNFα medication.

6 Sep 2021

Is the SARS-CoV-2 Lambda variant more vaccine-resistant than the Delta variant?

Researchers in the USA and China recently published a report in which they discussed the potential factors that confer high infectivity and immune resistance on the Delta and Lambda variants.

6 Sep 2021

Study finds SARS-CoV-2 affects the brain by binding with MAO enzymes

A new study by researchers in Croatia and Slovenia shows the SARS-CoV-2 spike protein has an affinity towards monoamine oxidases (MAO) enzymes. Changes in MAO levels have been the culprit for several neuropsychiatric disorders such as Parkinson’s or Alzheimer’s disease.

6 Sep 2021

Study finds a restricted number of possible escape mutations for SARS-CoV-2 Delta variant

The emergence of escape mutations in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is somewhat less likely for the Delta variant in comparison with the original or wild type virus, shows a recent study currently available on the bioRxiv* preprint server while it undergoes peer review.

5 Sep 2021

SARS-CoV-2 fusion peptides play distinct roles according to neutron scattering

A new study determines the physical and thermodynamic events associated with the interactions that lead to the fusion between SARS-CoV-2 and the host.

5 Sep 2021

Efficacy of vaccines against the SARS-CoV-2 Delta variant

A new study uses statistical models to determine vaccine efficacy against the various SARS-CoV-2 variants and clinical endpoints for SARS-CoV-2 variants.

5 Sep 2021

Immunological differences in Moderna and Pfizer-BioNTech vaccine-induced Fc-functional profiles

A new study analyzed the post-boost binding and functional capacity of the humoral response induced by the Pfizer-BioNTech and Moderna vaccines.

3 Sep 2021

Antibody cocktail neutralizes SARS-CoV-2 and has projected protection up to 12 months

A new study reports long-lasting, effective protection against severe disease with the AZD7442 antibody cocktail.

3 Sep 2021

CAR T cells expressing a natural RNA can activate the body’s own T cells against solid tumors

Chimeric antigen receptor (CAR) T cell therapy, which uses engineered T cells to treat certain types of cancers, has often been a challenging approach to treating solid tumors. CAR T cells need to recognize a specific target on cancer cells to kill them.

2 Sep 2021

Receptor News and Research

Breakthrough discovery could pave the way for new non-opioid painkillers to treat neuropathic pain

The role of nanobodies in capturing and containing SARS-CoV-2

New tool can rapidly quantify T cell fraction and predict immunotherapy response

Potential pancoronavirus fusion inhibitors that are effective against SARS-CoV-2 variants

Activated mast cell disorders potentially linked to SARS-CoV-2 immunity

Multiplexed electrochemical sensor platform enables simultaneous detection of SARS-CoV-2 RNA and host antibodies

Implications of persistent SARS-CoV-2 infection in patients with lymphoid malignancies

Maternal SARS-CoV-2 vaccination in early-third trimester may optimize neonatal seroprotection

Study sheds light on neurologic symptoms caused by SARS-CoV-2 infection

Increased infectivity and immune evasion drive the spread of Delta SARS-CoV-2 variant

New insights could help unlock the mystery of how lung cancer arises in never smokers

Decreased COVID-19 vaccine efficacy amongst IBS patients receiving anti-TNFα drugs

Is the SARS-CoV-2 Lambda variant more vaccine-resistant than the Delta variant?

Study finds SARS-CoV-2 affects the brain by binding with MAO enzymes

Study finds a restricted number of possible escape mutations for SARS-CoV-2 Delta variant

SARS-CoV-2 fusion peptides play distinct roles according to neutron scattering

Efficacy of vaccines against the SARS-CoV-2 Delta variant

Immunological differences in Moderna and Pfizer-BioNTech vaccine-induced Fc-functional profiles

Antibody cocktail neutralizes SARS-CoV-2 and has projected protection up to 12 months

CAR T cells expressing a natural RNA can activate the body’s own T cells against solid tumors

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News